Cognex’s Recovery Is Real — But Our Data Shows the Valuation Gap Is the Real Story

The Signal: A competitor outlet recently covered Cognex’s return to growth in the industrial machine vision market, noting the company’s AI-at-the-edge product momentum and improving financials. Our company intelligence database adds material depth to what that coverage captured.

---

Our Data

Our coverage intelligence on Cognex (Coverage Priority Score: 63, rated CONTENDER) tracks a company executing a genuine operational inflection — but one where the financial architecture deserves more scrutiny than most coverage provides.

The headline numbers are strong: Q4 2025 revenue rose 10% YoY to $252M, full-year adjusted EPS climbed 38%, and Cognex has now posted six consecutive quarters of adjusted EBITDA margin expansion. The balance sheet is fortress-grade — $642M in cash and investments, zero debt, with management guiding for greater than 100% free cash flow conversion in 2026. A new $500M share repurchase authorization, announced February 11, 2026, signals management confidence in sustained earnings power.

The margin roadmap is the most analytically interesting element. Management has identified $35–40M in specific 2026 opex reductions, is exiting approximately $22M of low-margin revenue, and is targeting a 25% adjusted EBITDA run-rate by end-2026 within a through-cycle framework of 25–31%. Pricing headwinds that compressed margins through 2024 are expected to reverse into tailwinds post-end-2025 — a structural shift that most coverage has underweighted.

On the product side, the In-Sight L38 3D launch — an edge-deployed AI system targeting bin-picking and assembly verification for collaborative and industrial robots — is the clearest signal of where Cognex is placing its AI bets. A March 2026 global manufacturer study released by the company confirmed demand for high-performance, low-integration-friction vision systems, validating the product direction.

Board composition also shifted materially on March 2, 2026: automation veteran Dr. Sami Atiya and software sales leader Chris Donato joined as directors, replacing long-tenured members Robert Willett and Dr. Dianne Parrotte. This is a deliberate repositioning toward AI and software-led commercial execution, not a routine refresh.

---

Product Portfolio — COGNEX

Signal Activity — COGNEX

Competitive Positioning — COGNEX

What They Missed

The coverage gap is the valuation-versus-execution tension that our CONTENDER rating is specifically designed to flag.

Cognex trades at approximately 39x forward P/E against a sector average of roughly 25x — a 56% premium that embeds near-perfect execution on simultaneous cost reduction, portfolio pruning, innovation velocity, and a 2H26-weighted semiconductor capex recovery. Any one of those variables slipping creates outsized downside at this multiple.

The Keyence competitive dynamic also received insufficient treatment. Keyence’s direct-sales model, rapid iteration cycles, and scale represent a structural constraint on Cognex’s pricing power and market share trajectory — not a one-cycle headwind. Our analysis rates this as a persistent moat-compression risk, not a manageable nuisance.

Additionally, FY2025 revenue of approximately $994M remains below prior cycle peaks, and the absence of named customer deployment case studies in publicly available materials makes independent verification of installed base depth difficult. The recovery is real; the depth of penetration in next-generation robotics applications is less proven than the stock price implies.

The 33.9% three-month share gain — outpacing AMETEK (+13.9%), OSI Systems (+4.5%), and Zebra (-13.2%) — reflects genuine momentum, but also compresses the margin of safety for new investors.

---

Bottom Line

Cognex is executing a credible operational recovery with a defensible AI roadmap, but at 39x P/E, investors are paying for flawless delivery on every lever simultaneously — and our data suggests the Keyence overhang and cycle-timing risk make that a demanding bet.